Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.61 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | WDR5 | P61964 | 7/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30410222 | 1.00 | ALDH1A1 (0.61) | ALDH1A1SIRT6LMNAGAAWDR5 | |
| SCHEMBL21590163 | 0.94 | LMNA (0.63) | ALDH1A1SIRT6LMNAGAAWDR5 | |
| SCHEMBL7049102 | 0.89 | GAA (0.60) | ALDH1A1LMNAGAAKMT2AMEN1 | |
| SCHEMBL427403 | 0.88 | SIRT6 (0.59) | ALDH1A1SIRT6LMNAGAAWDR5 | |
| SCHEMBL10036126 | 0.87 | ALDH1A1 (0.52) | ALDH1A1SIRT6LMNAGAAWDR5 | |
| SCHEMBL328462 | 0.87 | WDR5 (0.49) | ALDH1A1SIRT6LMNAGAAWDR5 | |
| SCHEMBL30464731 | 0.87 | WDR5 (0.49) | ALDH1A1SIRT6LMNAGAAWDR5 | |
| SCHEMBL10036447 | 0.87 | KMT2A (0.50) | ALDH1A1SIRT6LMNAGAAWDR5 | |
| Hydrochloric Acid SCHEMBL5827767 | 0.86 | SIRT6 (0.58) | ALDH1A1SIRT6LMNAGAAWDR5 | |
| SCHEMBL242441 | 0.86 | GAA (0.69) | ALDH1A1LMNAGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619406-A1 | TRICYCLIC COMPOUNDS | Schrödinger, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025042408-A1 | METHODS OF TREATING CANCER | SCHRÖDINGER, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3543242-B1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023217201-A2 | NOVEL PYRIMIDO-HETEROCYCLIC NOVEL COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATION THEREOF | 杭州德睿智药科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| CN-116143773-B | 2-amino-4-thiazolylpyrimidine compound and preparation method and application thereof | 中国药科大学 | 2023-07-21 | — | — | CN | disclosed |
| CN-113614087-B | WEE1 inhibitor and preparation and application thereof | 首药控股(北京)股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-116143773-A | 2-amino-4-thiazolylpyrimidine compound and preparation method and application thereof | 中国药科大学 | 2023-05-23 | — | — | CN | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-1694652-A1 | STEREOISOMERS AND STEREOISOMERIC MIXTURES OF 1-(2,4-PYRIMIDINEDIAMINO)-2-CYCLOPENTANECARBOXAMIDE SYNTHETIC INTERMEDIATES | Rigel Pharmaceuticals, Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060167249-A1 | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | US | disclosed |
| WO-2006055561-A2 | STEREOISOMERICALLY ENRICHED 3-AMINOCARBONYL BICYCLOHEPTENE PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060035891-A1 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | MIDCAP FINANCIAL TRUST | 2006-02-16 | — | — | US | disclosed |
| US-20050288515-A1 | Chemical compounds | SMITHLINE BEECHAM CORPORATION | 2005-12-29 | — | — | US | disclosed |
| WO-2005118544-A2 | CYCLOALKYL SUBSTITUTED PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050192301-A1 | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates | MIDCAP FINANCIAL TRUST | 2005-09-01 | — | — | US | disclosed |
| WO-2005063722-A1 | STEREOISOMERS AND STEREOISOMERIC MIXTURES OF 1-(2,4-PYRIMIDINEDIAMINO)-2-CYCLOPENTANECARBOXAMIDE SYNTHETIC INTERMEDIATES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1551813-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004032882-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192301-A1 | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates | PCNA, PAICS, DPYD | ALDH1A1 1230/4885SIRT6 2193/4885LMNA 1781/4885 |
| US-20060035891-A1 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | MKI67, PCNA, TK1 | ALDH1A1 1807/4885SIRT6 1987/4885LMNA 2917/4885 |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | ALDH1A1 3541/4885SIRT6 340/4885LMNA 3929/4885 |
| US-20060167249-A1 | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses | MKI67, PCNA, CCNI | ALDH1A1 705/4885SIRT6 2608/4885LMNA 3220/4885 |
| US-20050288515-A1 | Chemical compounds | CDK4, CDK2, CDK3 | ALDH1A1 1300/4885SIRT6 1630/4885LMNA 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.